Loading
Synthego
Synthego is a biotechnology company based in Redwood City, California, specializing in CRISPR-based genome engineering and molecular diagnostics. Founded in 2012, Synthego aims to accelerate life science research and therapeutic development through automated and precise genome editing solutions. The company integrates hardware, software, bioinformatics, chemistry, and molecular biology to provide comprehensive CRISPR tools for researchers and drug developers. Synthego offers a range of genome engineering services, including custom synthetic guide RNA design, genome editing cell line services, and high-throughput synthetic RNA production. Its product portfolio features synthetic guide RNA for CRISPR genome editing, CRISPR/Cas9 RNA kits, and molecular diagnostic reagents. The company serves a global customer base, including leading biotechnology firms and top universities, and collaborates on CRISPR research across various applications. Synthego continues to innovate in the field of genome editing, empowering scientific discovery and therapeutic advancements.
Funding
Every round, secondary, debt facility or acquisition involving Synthego that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$40M